847795-98-6

Usage

Uses

Used in Medicinal Chemistry:
Tert-butyl (8-syn)-3-azabicyclo[3.2.1]oct-8-ylcarbamate is used as a compound of interest for its potential applications in medicinal chemistry, given its unique molecular structure and the possibility of biological activity.
Used in Drug Development:
In the pharmaceutical industry, tert-butyl (8-syn)-3-azabicyclo[3.2.1]oct-8-ylcarbamate is used as a candidate molecule for drug development, with the aim of exploring its interactions with biological targets and its potential therapeutic effects. Further research is necessary to understand its full potential in this context.

Upstream product

• 847795-96-4 3-benzyl-N-hydroxy-3-azabicyclo[3.2.1]octan-8-imine 
• 166973-12-2 3-benzyl-3-azabicyclo[3.2.1]octan-8-amine 
• 83507-33-9 3-benzyl-3-aza-bicyclo[3.2.1]octan-8-one 
• 847862-25-3 exo-tert-butyl N-(3-benzyl-3-azabicyclo[3.2.1]octan-8-yl)carbamate 
• 847862-24-2 (1R,5S,8s)-3-benzyl-3-azabicyclo[3.2.1]octan-8-amine 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION EXO-TERT-BUTYL N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)CARBAMATE

The present invention relates to a process for the preparation of a compound (I) or pharmaceutically acceptable salt thereof, which is useful as the key intermediate for the synthesis of compounds for prophylaxis and treatment of a disease associated with

BRIDGED PIPERIDINE DERIVATIVES

The present invention relates to compounds of formula (l); hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N; hetaryl II is a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, or N, wherein at least one ring is aromatic in nature; R1 is lower alkyl, lower alkoxy, lower alkyl substituted by halogen or halogen; R2 is lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, cycloalkyl substituted by lower alkyl or lower alkyl substituted by halogen, or is lower alkyl substituted by hydroxy, or is furyl, or is O-benzyl, (CH2)p-phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkyl or by cyano; R3 is hydrogen or lower alkyl; Y is (CH2)n-, -CH2OCH2-, -CH2O-, CH2S-, -CH2SCH2- and is bonded to two of the ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; if m is 2 then R1 may be the same or different; -75- n is 2 or 3; o is 0, 1 or 2, if o is 2, then R2 may be the same or different; or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimers disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

BRIDGED PIPERIDINE DERIVATIVES

The present invention relates to compounds of formula I hetaryl I, hetaryl II, R1, R2, R3, Y, m, and o or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

NEW COMPOUNDS

The invention relates to new compounds of the general formula (I), which are strong DPP-IV enzyme inhibitors.